---
title: "Nucala (mepolizumab), all indications: Indication questions"
description: "Indication questions on Nucala (mepolizumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Drug names. Questions: What is the generic name of Nucala? What drug class is Nucala? When was Nucala first approved in the US? 3 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/nucala/indication"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Nucala (mepolizumab), all indications: Indication questions

Manufacturer: GlaxoSmithKline  
Prescribing information: [Nucala](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF)  
Indication pages: [Severe eosinophilic asthma](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma)

## Drug names

<a id="nucala-generic-name"></a>

### What is the generic name of Nucala?

> “NUCALA (mepolizumab) for injection, for subcutaneous use 
> NUCALA (mepolizumab) injection, for subcutaneous use”

Source: [NUCALA: Prescribing information, page 1, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=1)

<a id="nucala-drug-class"></a>

### What drug class is Nucala?

> “NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 
> kappa)”

Source: [NUCALA: Prescribing information, page 1, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=1)

> “Mepolizumab is a humanized IL-5 antagonist monoclonal antibody. Mepolizumab is produced 
> by recombinant DNA technology in Chinese hamster ovary cells.”

Source: [NUCALA: Prescribing information, page 15, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=15)

## Indication

<a id="nucala-approval-date"></a>

### When was Nucala first approved in the US?

> “Initial U.S. Approval: 2015”

Source: [NUCALA: Prescribing information, page 1, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=1)

## Related pages
- [Medical information: Nucala (mepolizumab): All indications](https://www.evicenter.com/medical-information/nucala)
- [Pharmacology](https://www.evicenter.com/medical-information/nucala/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/nucala/safety)
- [Specific populations](https://www.evicenter.com/medical-information/nucala/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/nucala/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/nucala/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/nucala/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/nucala/access-and-coverage)
